Navigation Links
U.S. Patent Office Issues Notice of Allowance for Patent Application Related to CTI's GlycoPolymer Technology
Date:11/20/2011

SEATTLE, Nov. 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively licensed to Aequus Biopharma, Inc. (Aequus), a majority owned subsidiary of CTI, for the purpose of development and commercialization. The patent application entitled "Conjugates of biologically active proteins having a modified in vivo half-life" has also been filed in other regions and countries, including Europe and Japan. Corresponding patents have been granted in New Zealand, South Africa and Singapore.  

"This U.S. Patent Allowance is an important milestone for Aequus and its development of the GlycoPolymer technology," said Stewart D. Chipman, Ph.D., President and CSO of Aequus. "We believe that this technology has the potential to significantly streamline the development of first-in-class therapeutic proteins and peptides, as well as extend the half-life of existing therapeutic proteins and peptides to improve their therapeutic profile through less frequent dosing, resulting in improved patient compliance. Our lead program, AQB-101, is a novel glycoprotein with G-CSF-like activity that demonstrates an extended plasma half-life.  Aequus is currently generating in vivo data to demonstrate AQB-101's utility, and we look forward to further development of AQB-101 and the GlycoPolymer technology," Dr. Chipman concluded.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

About Aequus BioPharma, Inc.

Headquartered on Bainbridge Island, WA, Aequus BioPharma is a biopharmaceutical company committed to streamlining the development of biopharmaceuticals with improved pharmacokinetic properties in a wide variety of human disease indications. Aequus Biopharma is a majority owned subsidiary of Cell Therapeutics. For additional information, please visit www.aequusbiopharma.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of GlycoPolymer technology include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with  the GlycoPolymer technology in particular including, without limitation, the potential failure to prove safe and effective, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
2. MedBox Develops Patent-Pending System for Storage and Retrieval of Prescription Drugs
3. RSB Spine, LLC, Announces European Patent Allowance
4. Awarepoint Advances Industry Leadership with New Patented Technology
5. Watson Confirms Exelon(R) Patent Challenge
6. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
7. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
8. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
9. Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott
10. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
11. Life Spine Awarded Seven New Patents, Launches Six New Product Lines & Realizes 25% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):